Understanding the impact of long COVID in Brazil

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This national retrospective cohort study aims to enroll 1,694 adult patients diagnosed with COVID-19 during the omicron wave in Brazil. Participants will be recruited online and assessed for the incidence and potential risk factors associated with post-acute COVID-19 syndrome, as well as its impact on health-related quality of life. The study focuses on individuals who experienced symptomatic COVID-19 after January 2022 and evaluates outcomes at least 90 days post-diagnosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years;
* Brazilian resident;
* Symptomatica COVID-19 confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) or antigen test for SARS-COV-2 after January 2022, with diagnosis at least 90 days before recruitment.

Exclusion Criteria:

* No availability to participate in remote research appointments;
* Communication difficulty (aphasia, important hearing loss, non-portuguese speaker, severe dementia)
* Refuse to provide informed consent

Where it's running

• Inova Medical
  Cachoeirinha, Rio Grande do Sul, Brazil Recruiting

Study contacts

• Study coordinator: Maicon Falavigna, MD, PhD
• Email: maicon@inovamedical.com.br
• Phone: +5551994408818

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Second cohort following patients entering a multidisciplinary care pathway for post-COVID syndromes (SyPoCo2)

  This project will test whether linking long COVID patients' symptoms with blood immune and molecular markers can find biomarkers and possible treatment targets.

  Recruiting at 2 sites Hospices Civils de Lyon · Pierre-Bénite and 1 other locations · NCT07356570

• Accelerated intermittent theta-burst stimulation for depression with post‑COVID‑19 condition

  This will test whether two different schedules of intermittent theta-burst stimulation (accelerated TMS) reduce depressive symptoms and inflammation in adults aged 18–65 who have depressive disorder plus post‑COVID‑19 condition.

  Recruiting Max-Planck-Institute of Psychiatry · Munich, Bavaria · NCT07197138

• 2-HOBA to reduce persistent immune activation in Long COVID with POTS

  This trial will test whether 2‑HOBA, a compound that scavenges harmful IsoLG-adducts, can reduce immune activation in adults with Long COVID who have POTS.

  Recruiting Phase 2 Vanderbilt University Medical Center · Nashville, Tennessee · NCT07189936

• Long COVID relief through learning mindfulness

  This study will try an 8-week online recorded mindfulness program to see if it reduces stress and Long COVID symptoms in adults who continue their usual care.

  Recruiting Columbia University · New York, New York · NCT07140094

• Investigating dysfunctional breathing in patients with post COVID-19 condition

  This study is trying to see how breathing problems affect people who are dealing with long-term symptoms after having COVID-19.

  Recruiting Karolinska Institutet · Stockholm, Solna and 1 other locations · NCT06776263

• Evaluating Apabetalone for Long-COVID in Diabetes Patients

  This study is testing if adding a new medication called Apabetalone to the diabetes drug dapagliflozin can help people with Type 2 Diabetes who are dealing with Long-COVID symptoms feel better.

  Recruiting Phase 2/3 Resverlogix Corp · Amman and 2 other locations · NCT06590324

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.